Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. is an Israeli biopharmaceutical company with a platform technology that addresses inflammatory diseases, cancer, and ophthalmic indications currently conducting clinical trials in the U.S., Europe and Israel.
History
Can-Fite BioPharma Ltd. was founded in 2000 in Israel by current CEO Pnina Fishman, Ph.D., a researcher at the Rabin Medical Center, and Ilan Cohn, Ph.D., a patent attorney and senior partner at Reinhold Cohn Patent Attorneys.
The company is developing small molecule drugs targeting the A3 adenosine receptor that it licensed from the US National Institutes of Health Office of Technology Transfer invented by Kenneth Jacobson, head of the molecular recognition section of the National Institute of Diabetes & Digestive & Kidney Diseases. Fishman had recognized that cancer does not metastasize to muscle cells, had gone hunting for a factor that muscles might secrete that could resist cancer, and had discovered that muscle cells secrete A3 adenosine receptor agonists.
By 2004 Can-Fite had raised $15.7 million in seed and two financing rounds, by 2010 it had raised $20 million from venture capital and $30 million from public markets, and in November 2013 it started trading on the New York Stock Exchange.
Subsidiaries
Can-Fite's subsidiary, OphthaliX Inc., is a clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders.
Development Collaborations
In 2006, Can-Fite entered into an exclusive Japanese license agreement with Seikagaku Corporation (SKK), a Research and Development-oriented pharmaceutical company.
Can-Fite has also signed an exclusive license with Kwang Dong Pharmaceutical Co., Ltd., to distribute CF101 for arthritis in Korea.
History
Can-Fite BioPharma Ltd. was founded in 2000 in Israel by current CEO Pnina Fishman, Ph.D., a researcher at the Rabin Medical Center, and Ilan Cohn, Ph.D., a patent attorney and senior partner at Reinhold Cohn Patent Attorneys.
The company is developing small molecule drugs targeting the A3 adenosine receptor that it licensed from the US National Institutes of Health Office of Technology Transfer invented by Kenneth Jacobson, head of the molecular recognition section of the National Institute of Diabetes & Digestive & Kidney Diseases. Fishman had recognized that cancer does not metastasize to muscle cells, had gone hunting for a factor that muscles might secrete that could resist cancer, and had discovered that muscle cells secrete A3 adenosine receptor agonists.
By 2004 Can-Fite had raised $15.7 million in seed and two financing rounds, by 2010 it had raised $20 million from venture capital and $30 million from public markets, and in November 2013 it started trading on the New York Stock Exchange.
Subsidiaries
Can-Fite's subsidiary, OphthaliX Inc., is a clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders.
Development Collaborations
In 2006, Can-Fite entered into an exclusive Japanese license agreement with Seikagaku Corporation (SKK), a Research and Development-oriented pharmaceutical company.
Can-Fite has also signed an exclusive license with Kwang Dong Pharmaceutical Co., Ltd., to distribute CF101 for arthritis in Korea.
Comments